Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ryan L Crass"'
Autor:
Felix Agbo, Ryan L. Crass, Yu‐Yuan Chiu, Sunny Chapel, Gerald Galluppi, David Blum, Bradford Navia
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1464-1475 (2021)
Abstract Apomorphine is an on‐demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD). A joint parent‐metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine‐sulfate following admini
Externí odkaz:
https://doaj.org/article/707bf860bbef4634a0b0eed862316d5e
Autor:
Manjunath P. Pai, Ryan L. Crass
Publikováno v:
Antibiotics, Vol 10, Iss 11, p 1368 (2021)
Antibiotic efficacy determination in clinical trials often relies on non-inferiority designs because they afford smaller study sample sizes. These efficacy studies tend to exclude patients within specific populations or include too few patients to di
Externí odkaz:
https://doaj.org/article/46f5a6ded1c342ffb82ceb1bcc207edc
Autor:
Satyawan B. Jadhav, Benny M. Amore, Howard Bockbrader, Ryan L. Crass, Sunny Chapel, William J. Sasiela, Maurice G. Emery
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics.
Population pharmacokinetics (popPK) of bempedoic acid and the popPK/pharmacodynamic (popPK/PD) relationship between bempedoic acid concentrations and serum low-density lipoprotein cholesterol (LDL-C) from baseline were characterized. A two-compartmen
Autor:
Madeline A Lipp, Ryan L Crass, Linda J Fitzgerald, Twisha S Patel, Richard H Simon, Blair E Lenhan, MeiLan K Han, Shijing Jia
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:2516-2521
Objectives Colistimethate sodium and tobramycin are important systemic antibiotics for treatment of cystic fibrosis (CF) pulmonary exacerbations but can induce acute kidney injury (AKI). We characterize the rate of AKI in CF patients treated with sys
Autor:
Elizabeth Leung, Ryan L. Crass, Sarah C. J. Jorgensen, Sumit Raybardhan, Bradley J. Langford, W. Justin Moore, Nathaniel J. Rhodes
Publikováno v:
Clinical Pharmacokinetics
Tocilizumab is one of few treatments that have been shown to improve mortality in patients with coronavirus disease 2019 (COVID-19), but increased demand has led to relative global shortages. Recently, it has been suggested that lower doses, or fixed
Autor:
Gerald F. Watts, Satyawan B Jadhav, Sunny Chapel, Benny M. Amore, Alberico L. Catapano, P. Hugh R. Barrett, Ryan L Crass, Maurice G. Emery, Michael Kerschnitzki, William J. Sasiela
Publikováno v:
European Heart Journal - Cardiovascular Pharmacotherapy. 8:578-586
Aims Many patients are unable to achieve guideline-recommended LDL cholesterol (LDL-C) targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a competitive inhibitor of ATP citrate lyase, significantly lowers LDL-C with o
Autor:
Bradford Navia, Gerald Galluppi, David Blum, Sunny Chapel, Ryan L Crass, Felix Agbo, Yu-Yuan Chiu
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1464-1475 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1464-1475 (2021)
Apomorphine is an on-demand treatment of "OFF" episodes in patients with Parkinson's disease (PD). A joint parent-metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine-sulfate following administration of apomorphi
Autor:
Tamara Al Naimi, Ryan L. Crass, Bo Wen, Shijing Jia, Ernane Souza, Manjunath P. Pai, Susan Murray
Publikováno v:
Antimicrob Agents Chemother
Background: The optimal polymyxin B dosage needed to achieve an efficacy target of 50-100 mg·h/L when treating multi-drug-resistant bacterial infections in adult cystic fibrosis (CF) patients is unclear. The pharmacokinetics of intravenous polymyxin
Autor:
Elizabeth Leung, W. Justin Moore, Sumit Raybardhan, Ryan L. Crass, Bradley J Langford, Sarah C.J. Jorgensen, Nathaniel J. Rhodes
Tocilizumab is one of few treatments that have been shown to improve mortality in patients with COVID-19, but increased demand has led to relative global shortages. Recently, it has been suggested that lower doses, or fixed doses, of tocilizumab coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de5684f5a62070aeaf33376ad8afe3c0
https://doi.org/10.1101/2021.08.28.21262692
https://doi.org/10.1101/2021.08.28.21262692
Publikováno v:
Anaesthesia Critical Care & Pain Medicine. 39:27-29